Explore

TrendlineTrendline
China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials
TrendlineTrendline
Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion

Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion

Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion
TrendlineTrendline
Boehringer Ingelheim Expands Oncology Pipeline with $7.4 Billion Deal with China's Sino Biopharmaceutical

Boehringer Ingelheim Expands Oncology Pipeline with $7.4 Billion Deal with China's Sino Biopharmaceutical

Boehringer Ingelheim Expands Oncology Pipeline with $7.4 Billion Deal with China's Sino Biopharmaceutical
TrendlineTrendline
Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion

Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion

Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
TrendlineTrendline
Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug

Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug

Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug
TrendlineTrendline
Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI

Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI

Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI
TrendlineTrendline
U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act

U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act

U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act
Rapid ReadRapid Read
Immuto Scientific to Present Novel Drug Target Data for Colorectal Cancer and AML at Upcoming Conferences

Immuto Scientific to Present Novel Drug Target Data for Colorectal Cancer and AML at Upcoming Conferences

Immuto Scientific, an AI-enabled therapeutics company, announced it will present structural surfaceomics data on novel drug targets for colorectal cancer (CRC) and acute myeloid leukemia (AML) at two upcoming conferences: the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics and the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. At ENA 2026, Immuto will present research from its collaboration with the University of Wisconsin-Madison, focusing on identifying new target opportunities in patient-derived RAS colorectal cancer models. At ASH 2026, the company will present preclinical data on IMTO-4842.1, a mutation-agnostic antibody-drug conjugate (ADC) targeting an AML-specific surface protein conformer. These presentations aim to demonstrate how Immuto's structural surfaceomics platform uncovers disease-specific targets defined by changes in protein structure on the cell surface.
TrendlineTrendline
Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE
TrendlineTrendline
Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline
TrendlineTrendline
FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies